Hims & Hers Health, Inc. (HIMS)
| Market Cap | 6.08B |
| Revenue (ttm) | 1.24B |
| Net Income (ttm) | 101.26M |
| Shares Out | 218.48M |
| EPS (ttm) | 0.44 |
| PE Ratio | 62.65 |
| Forward PE | 51.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,117,971 |
| Open | 27.69 |
| Previous Close | 27.94 |
| Day's Range | 25.56 - 28.09 |
| 52-Week Range | 8.20 - 35.02 |
| Beta | 1.30 |
| Analysts | Buy |
| Price Target | 26.21 (-5.89%) |
| Earnings Date | Feb 24, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
In 2023, Hims & Hers Health's revenue was $872.00 million, an increase of 65.49% compared to the previous year's $526.92 million. Losses were -$23.55 million, -64.15% less than in 2022.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for HIMS stock is "Buy." The 12-month stock price forecast is $26.21, which is a decrease of -5.89% from the latest price.
News
Hims & Hers: Ready To Outperform Further
Hims & Hers Health is a rapidly growing telehealth leader with a unique, customer-focused business model, demonstrated by its aggressive customer base expansion and accelerating revenue growth momentu...
Hims & Hers Health: The Market Is Likely Wrong
Hims & Hers Health is undervalued despite impressive growth, with analysts overly focused on compounded GLP-1s and potential FDA restrictions. BoA's negative outlook contrasts with Hims' projected 90%...
Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns
Hims & Hers capitalizes on telehealth growth in hair, mental, sexual health, and weight loss. Yet, limited product differentiation, reliance on branding, and FDA risks weaken its long-term moat. Forec...
Hims & Hers donates $1 million to Trump's inauguration fund
Hims & Hers Health has donated $1 million to President-elect Donald Trump's inauguration fund, CNBC confirmed Tuesday. The company is the latest in a string of tech organizations that have tried to cu...
Hims & Hers: Ready For Liftoff In 2025
Despite a recent 30% stock drawdown, Hims & Hers Health, Inc. remains a “Strong Buy” due to its undervaluation and long-term growth potential in the healthcare tech market. Hims & Hers' robust Q3 2024...
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health com...
Hims & Hers: Still Trading At A Massive Discount
Hims & Hers Health is revolutionizing telehealth with a vertically integrated model, offering personalized medications and achieving rapid subscription growth, driving long-term profitability and diff...
Will the falling Hims & Hers stock price recover in 2025?
Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped by almost 200% this year, while other companies in the industry like CVS Hea...
The Shape of America 2024: Hims & Hers Shares an In-Depth Look Into How Americans Feel About Weight
SAN FRANCISCO--(BUSINESS WIRE)--For most Americans, weight is more than just a number. It shapes our health, our mood, our confidence, our spending, and the decisions we make in our day to day lives. ...
Hims & Hers: Look At What Matters Most
Hims & Hers Health, Inc. has shown significant improvement in key unit economics, positioning it among top-tier SaaS companies in terms of scalability and growth potential. The company reported stella...
Options Action: Bearish bets on Hims
Mike Khouw joins 'Fast Money' to talk the options trade around Hims.
Market Navigator: Hims & Hers Health up 250% in 2024
Todd Gordon, founder of Inside Edge Capital, joins CNBC's 'Power Lunch' to discuss why he's keeping an eye on shares of these healthcare picks, potential headwinds, and more.
Hims & Hers: The Show Must Go On
Hims & Hers Health stock is substantially undervalued despite a massive YTD rally, presenting a strong buy opportunity due to a myriad of catalysts. The company demonstrates exponential revenue growth...
Stock Picks From Seeking Alpha's November 2024 New Analysts
Twenty-six new analysts joined Seeking Alpha in November, sharing diverse investment ideas highlighting their unique backgrounds and expertise. Top picks include U.S. Bancorp Preferred Series A, Hersh...
Hims & Hers Vs. Amazon: Why David Defeats Goliath
Hims & Hers has shown significant growth in the telehealth market, facing competition mainly from Amazon, but has unique advantages. HIMS's agility, focused resource allocation, and strong market fit ...
Hims & Hers Named to Inc.'s 2024 Best in Business List in Health Products Category
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, is proud to announce its inclusion on the Inc. 2024 Best in Business lis...
Hims & Hers: Driving Growth In Wellness
Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Q3 2024 revenue rose 77% YoY to $401.6M, with $392.6M from online channels (+79% YoY). GLP-1 patient retention at...
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.
Health care stocks jump on Trump's nominee for FDA head
CNBC's Angelica Peebles joins 'Fast Money' to talk president-elect Trump's pick for FDA head.
What's Happening With HIMS Stock?
The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has risen a solid 14% in a week. Much of this move came after the U.S. FDA asked for more time to confirm the shortage of Eli...
The FDA Can't Decide Whether Zepbound Is in Shortage. It's Good News for Hims & Hers Stock.
Hims & Hers markets a compounded version of a similar medicine sold by Novo Nordisk.
Hims & Hers Expands Nutrition Support to Fuel Customers' Weight Loss Journeys
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that Hims & Hers customers will now be able to supplemen...
Hims & Hers Health: Far From Dead, Even With Amazon's Threat Ahead
Hims & Hers Health can potentially face significant competition from Amazon's aggressive pricing and broad telehealth offerings, but its personalized care and strong financials offer resilience. Not e...
Hims & Hers Appoints Tenured Pharmaceutical, Regulatory, and Quality Experts to Key Leadership Positions
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS), the leading health and wellness platform, today announced Deb Autor, former deputy commissioner at the FDA, will ...